ClinicalTrials.gg
RecruitingNCT05814094ROSETTAUpdated May 31, 2025

Red Blood Cell Transfusion in ECMO - A Feasibility Trial

An interventional study of Red Blood Cell Transfusion and Red Blood Cell Transfusion in Blood Loss Anemia, Extracorporeal Membrane Oxygenation Complication and Disability Physical, sponsored by Australian and New Zealand Intensive Care Research Centre. Recruiting at 2 sites in Australia. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-31.

Sponsored by Australian and New Zealand Intensive Care Research Centre · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Started Sep 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 30 studies in Hemorrhage with a site in Australia — 7 open to participants now, 11 under way, 7 of them phase 3. Hemorrhage · Australia.

Planned enrollment
17th of 26
120 · median 212
Started
2023
the only one that year
No phase
4 of 30
1 open now
Primary completion
2025-01
later than 1 of 10 live
Registered
25th of 30
by date
Lead sponsor
2 of 30
Australian and New Zealand Intensive Care Research Centre

Among the 30 studies in Hemorrhage with a site in Australia, this one is the 17th largest by planned enrollment of the 26 interventional ones that give a count, is the only one that started in 2023, is one of 4 with no phase, reaches primary completion later than 1 of the 10 other live ones, and was the 25th registered.

Hemorrhage

1,384 studies on the registry are indexed under Hemorrhage; 245 are open to participants now.

Browse Hemorrhage studies →

Open to participants now

7 of the 30 studies in Hemorrhage with a site in Australia are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 171 Hemorrhage studies recruiting now, 109 (64%) set no upper age limit and 41 (24%) stop at 75 or younger; 26 take children under 18; 21 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Hemorrhage with a site in Australia, or all of them as a file.
02

Study summary

Extracorporeal Membrane Oxygenation (ECMO) is an invasive and resource intense treatment used to support critically ill patients who have suffered severe cardiac arrest, cardiac failure or respiratory failure (including severe cases of COVID-19). ECMO acts as a mechanical circulatory support temporarily replacing the function of the heart or lungs by oxygenating blood and removing carbon dioxide, allowing time for these organs to recover. Many critically ill patients, including those on ECMO, have an increased risk of bleeding and reduced production/increased destruction of red blood cells (RBCs). This can lead to anaemia (haemoglobin levels \<120 g/l), a condition where the body lacks enough healthy RBCs to carry enough oxygen to the body's tissues. Therefore, patients on ECMO frequently require RBC transfusion, with clinicians having to decide if administering an RBC transfusion (with its associated risks) is higher than tolerating complications of anaemia.

ROSETTA is a feasibility study that aims to determine the safety and feasibility of randomizing patients on ECMO to a restrictive RBC transfusion strategy (maintain Hb concentration above 70g/L) or to a more liberal transfusion strategy (maintain Hb concentration above 90g/L). Feasibility is defined as the ability to achieve a mean separation of at least 10g/L between the average lowest daily haemoglobin values in the two study groups.

Read the detailed description

A recent Cochrane analysis recommended a transfusion strategy that minimises the use of RBC transfusions in critically ill patients (by tolerating anaemia to avoid the adverse effects of an RBC transfusion). However, the analysis acknowledges that the degree of anaemia which can be tolerated by such patients is unknown, especially in patients suffering from conditions that limit oxygen delivery to the organs (like cardiac disease). As a result, the Australian Blood Authority's guidelines recommend an RBC transfusion to a patient at an Hb concentration of less than 70 g/L, while a transfusion at a Hb between 70 and 90 g/L should be based on the need to relieve clinical signs and symptoms of anaemia. However, this range is broad, and many studies in the general critically ill cohort have shown lower transfusion triggers are non-inferior to higher transfusion triggers.

No studies have been completed directly evaluating transfusion triggers in the ECMO patient cohort. ECMO patients differ to the general critically ill cohort as they have different physiological requirements, are at higher-risk for poor outcomes, and have an increased requirement for transfusions. Hb is a key driver of oxygen delivery (DO2), and critically ill ECMO patients are more commonly exposed to low DO2 due to low cardiac output and borderline oxygenation. Therefore, studies must be done to evaluate the optimal transfusion trigger/s (as determined by Hb concentration) that optimise mortality and long-term outcomes of ECMO patients.

Should the ROSSETTA Pilot results indicate adequate separation of at least 10g/L between the two study groups, and that patient safety has not been adversely affected by the trial methods, feasibility will be deemed confirmed and the protocol not in need of modification prior to full trial commencement. At this point the ROSETTA Pilot will be transitioned into the Red Blood Cell Transfusion Domain, within RECOMMEND Platform Trial. The Primary and Secondary outcomes of the trial at large, will be answered during this stage.

03

Conditions studied

  • Blood Loss Anemia
  • Extracorporeal Membrane Oxygenation Complication
  • Disability Physical
  • Cognitive Ability, General
  • Functional Status

Browse trials for

Keywords

  • Hb
  • RBC transfusion
  • ECMO
  • feasibility
  • safety
  • blood transfusion
  • Australia
  • blood products
  • ICU
  • critical care
  • intensive care
  • bleeding
  • transfusion
  • Hb values
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients receiving ECMO
  • Age: 18 years or older

Exclusion criteria

Exclusion Criteria:

  • to RBC transfusion (including known patient preference)
  • Limitations of care put in place either through patient wishes or the treating medical teams
  • ECMO treatment for more than 12 hours. The start of ECMO is defined as the time of initiation of extracorporeal blood flow unless ECMO was initiated during a surgical intervention in which case the start is defined as the arrival time into the initial ICU.
  • The treating physician anticipates that ECMO treatment will cease before the end of tomorrow
  • Where the treating physician deems the study is not in the patient's best interest
  • Where the treating physician has concern regarding patient ability to tolerate restrictive or liberal transfusion trigger thresholds
  • Patients actively listed for a solid organ transplant
  • Patients who are suspected or confirmed to be pregnant
  • Previous ECMO treatment during the same hospital admission
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Active comparator
    Restrictive Transfusion Trigger Group

    if a patient's Hb concentration reads ≤ 70g/L, one unit of RBC will be transfused. Additional units can be prescribed if required to raise the Hb concentration to above 70g/L.

    Other: Red Blood Cell Transfusion

  • Active comparator
    Liberal Transfusion Trigger Group

    if a patient's Hb concentration reads ≤ 90g/L, one or more units of RBC will be transfused. Additional units can be prescribed to raise the Hb concentration to greater than 90g/L

    Other: Red Blood Cell Transfusion

Interventions

  • OtherRed Blood Cell Transfusion

    Following randomisation, if a patient's Hb concentration reads ≤ 70g/L, one unit of RBC will be transfused within 12 hours of the result becoming available. Additional units can be prescribed if required to raise the Hb concentration to above 70g/L. A transfusion above the restrictive threshold of 70g/L is discouraged.

  • OtherRed Blood Cell Transfusion

    Following randomisation, if a patient's Hb concentration reads ≤ 90g/L, one or more units of RBC will be transfused in order to raise the Hb concentration to greater than 90g/L within 12 hours of the result becoming available. A decision not to transfuse below the threshold of 90g/L is discouraged.

06

What researchers measure

Primary outcomes

  1. Difference in average lowest daily Hb concentration

    Primary Outcome Measure

    Time frame: From date of randomization to the end of the intervention (assessed up to day 28)

Secondary outcomes

  1. Enrolment Rate

    Feasibility Outcome

    Time frame: through study completion, an average of 2 years

  2. Reasons for not entering eligible patients into the study

    Feasibility Outcome

    Time frame: through study completion, an average of 2 years

  3. Mean pre-transfusion Hb concentration immediately prior to an RBC transfusion

    Feasibility Outcome

    Time frame: through study completion, an average of 2 years

  4. Proportion of RBC transfusions given according to allocated trigger

    Feasibility Outcome

    Time frame: through study completion, an average of 2 years

  5. Time from measured Hb trigger value to transfusion

    Feasibility Outcome

    Time frame: through study completion, an average of 2 years

  6. Number of RBC transfusions given prior to randomization

    Feasibility Outcome

    Time frame: through study completion, an average of 2 years

  7. Frequency for not transfusing a patient who has reached a transfusion trigger

    Feasibility Outcome

    Time frame: through study completion, an average of 2 years

  8. Reason/s for not transfusing a patient who has reached a transfusion trigger

    Feasibility Outcome

    Time frame: through study completion, an average of 2 years

  9. Number of protocol deviations

    Feasibility Outcome

    Time frame: through study completion, an average of 2 years

  10. Number and nature of Serious Adverse Events (SAEs)

    Safety and effectiveness outcome

    Time frame: through study completion, an average of 2 years

  11. Total blood products used

    Safety and effectiveness outcome

    Time frame: through study completion, an average of 2 years

  12. Major bleeding events (defined by ISTH criteria)

    Safety and effectiveness outcome

    Time frame: through study completion, an average of 2 years

  13. Clinically relevant non-major bleeding events: GI haemorrhage, peripheral cannulation site bleeding, mediastinal cannulation site bleeding, surgical site bleeding

    Safety and effectiveness outcome

    Time frame: through study completion, an average of 2 years

  14. Venous and arterial thromboembolic events

    Safety and effectiveness outcome

    Time frame: through study completion, an average of 2 years

  15. New onset renal replacement therapy (RRT) during ECMO

    Safety and effectiveness outcome

    Time frame: through study completion, an average of 2 years

  16. ECMO free days at day 60

    Safety and effectiveness outcome

    Time frame: 60 days

  17. ICU free days at day 60

    Safety and effectiveness outcome

    Time frame: 60 days

  18. Patient Reported Outcome Measure - WHODAS 2.0

    Disability Safety and effectiveness outcome

    Time frame: 6 months

  19. Patient Reported Outcome Measure - IADL

    Independent Activities of Daily Living Safety and effectiveness outcome

    Time frame: 6 months

  20. Patient Reported Outcome Measure - ADL

    Activity of Daily Living Safety and effectiveness outcome

    Time frame: 6 months

  21. Patient Reported Outcome Measure - MoCA BLIND

    Cognitive Function Safety and effectiveness outcome

    Time frame: 6 months

  22. Patient Reported Outcome Measure - EQ-5D-5L

    Quality of Life Safety and effectiveness outcome

    Time frame: 6 months

  23. Patient Reported Outcome Measure - mRS

    Degree of Disability Safety and effectiveness outcome

    Time frame: 6 months

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Patient data is de-identified and only aggregate summaries published.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2023 to primary completion in Jan 2025, 16 months.

Of 192 non-industry interventional studies with no phase under Hemorrhage, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's 16 months is below that.

Counting every sponsor, half of 227 studies reached it within 19 months; a quarter within 9 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 22, 2022
First posted
Apr 14, 2023
StartActual
Sep 20, 2023
Primary completionActual
Jan 30, 2025
CompletionEst.
Dec 30, 2025
Last update
May 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05814094
Lead sponsor
Australian and New Zealand Intensive Care Research Centre
Responsible party
Sponsor
First posted
Apr 14, 2023
Start date
Sep 20, 2023
Primary completion
Jan 30, 2025
Completion
Dec 30, 2025 (estimated)
Last update
May 31, 2025

Study contacts

Curtis Hopkins, B.BioMed, MPH, MHA
Contact
anzicrc@monash.edu
+61 3 9903 0343
Hergen Buscher, MBBS
principal investigator · St Vincent's Hospital, Sydney
Zoe McQuilten, PhD
principal investigator · Monash University
Carol Hodgson, PhD
principal investigator · Monash University
Alistair Nichol, PhD
principal investigator · Monash University
Aidan Burrell, MBBS
principal investigator · Monash University
Mark Dennis, MBBS
principal investigator · Royal Prince Alfred Hospital, Sydney, Australia
Timothy Southwood, MBBS
principal investigator · Royal Prince Alfred Hospital, Sydney, Australia
Alisa Higgins, PhD
principal investigator · Monash University
Sally Newman, Nursing
principal investigator · St Vincent's Hospital, Sydney
Thao Le, PhD
principal investigator · Monash University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion